Biotricity Reports 16.5% Revenue Growth to $11.75 Million, Reduces Net Loss

Biotricity Inc. reported a significant improvement in its financial performance for the nine months ended December 31, 2025, with total revenue reaching $11.75 million, a 16.5% increase from $10.09 million in the same period of the previous year. The company achieved a gross profit of $9.55 million, reflecting a gross margin of 81.3%, up from 75.2% in the prior year. This increase in gross margin was attributed to enhanced efficiencies in technology fee revenue and improved margins on device sales. Despite these gains, Biotricity recorded a net loss of $2.08 million, a notable reduction from a loss of $6.49 million in the prior year, indicating a positive trend in operational profitability.

The company’s operational expenses decreased to $8.55 million from $9.18 million year-over-year, primarily due to a 12.7% reduction in selling, general, and administrative expenses, which fell to $6.63 million. Research and development expenses increased to $1.92 million, reflecting ongoing investments in product development. Interest expenses rose slightly to $2.52 million, while accretion and amortization expenses significantly decreased to $0.54 million from $1.78 million, indicating a reduction in the cost of capital.

Biotricity has made strategic advancements, including the launch of its Biocore and Biocare products, which are expected to enhance its market presence. The company has expanded its sales efforts to 35 states and aims to penetrate the broader U.S. market. As of December 31, 2025, Biotricity reported a working capital deficiency of $18.82 million, up from $16 million in the previous year, raising concerns about its liquidity. The company has acknowledged substantial doubt about its ability to continue as a going concern, emphasizing the need for additional funding to support operations and growth initiatives.

In terms of operational metrics, Biotricity has monitored over two billion heartbeats for atrial fibrillation, benefiting more than 28,000 patients. The company’s focus on recurring technology fee revenue has been a key driver of its growth strategy, with technology fees accounting for 89.5% of total revenue in the latest reporting period. The company plans to continue expanding its sales force and product offerings to capitalize on the growing demand for remote cardiac monitoring solutions.

Looking ahead, Biotricity anticipates continued revenue growth and improved liquidity through business development and additional capital raises. The company is actively pursuing new financing opportunities to support its operations and product development, while also managing costs to achieve positive cash flow and profitability.